Dana Tegzová

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann et al. · Arthritis & Rheumatism · 2013 · 582 citations

Medicine, Internal Medicine, Pharmacotherapy +14

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study

Jakub Závada, S Sinikka Pešičková, Romana Ryšavá et al. · Lupus · 2010 · 126 citations

Pharmacy, Nephrology, Pharmacotherapy +13

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase <scp>III</scp> Study

Désirée van der Heijde, Vibeke Strand, Yoshiya Tanaka et al. · Arthritis & Rheumatology · 2019 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial

Winn Chatham, Daniel J. Wallace, William Stohl et al. · The Journal of Rheumatology · 2012 · 95 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17